Intrapleural Administration of an AAVrh.10 Vector Coding for Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Alpha-1 antitrypsin (α1AT) deficiency is a common autosomal recessive disorder characterized by a marked reduction in serum α1AT levels, lung and liver disease. α1AT is mainly produced and secreted by hepatocytes, with its primary function to protect the lung against the proteolytic activity of neutrophil elastase. Serum α1AT levels <11 μM are associated with progressive destruction of lung parenchyma and early-onset of panacinar emphysema in the age range 35-45. The current approved treatment for α1AT deficiency is a costly protein augmentation therapy requiring weekly intravenous infusion of purified α1AT from pooled human plasma. Gene therapy offers the advantage of a single vector administration, eliminating the burden of the repeated purified protein infusions, with the consequent reduced overall drug cost and improved compliance. We have developed a novel, highly efficient gene therapy approach for α1AT deficiency based on the administration of AAVrh.10hα1AT, an adeno-associated viral vector serotype rh.10 coding for normal M-type human α1AT via the intrapleural route. On the basis of prior murine studies, this approach provides sustained α1AT proximal to the lung with a highly efficient vector. In support of a clinical trial for this approach, we carried out a study to assess the safety of intrapleural administration of AAVrh.10hα1AT to 280 mice and 36 nonhuman primates. The data demonstrate that this approach is safe, with no toxicity issues. Importantly, there was persistent expression of the human α1AT mRNA in chest cavity cells for the duration of the study (6 months in mice and 1 year in nonhuman primates). Together, these data support the initiation of a clinical trial of intrapleural human AAVrh.10hα1AT for the treatment of α1AT deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327 · cited 4×
“The plasma a 1AT protective threshold of 11 l M has been the target of the ongoing clinical trials that use intra-muscular delivery of either AAV1 or AAV2 (Brantly et al. , 2006, 2009; Mueller and Flotte, 2013).”
InfluentialDe, B. P., Heguy, A., Hackett, N. R., Ferris, B., Leopold, P. L., Lee, J., Pierre, L., Gao, G., Wilson, J. M., & Crystal, R. G. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.003 · Cited by 129 · cited 6×
“AAV-mediated delivery of a 1AT offers an ideal strategy mediating sustained transgene expression (De et al. , 2004, 2006; Brantly et al. , 2006, 2009; Lu et al. , 2006; Chulay et al. , 2011; Flotte and Mueller, 2011; Mueller and Flotte, 2013) with the rh.10 serotype providing robust expression…”
InfluentialSelf-citationHackett, N. R., Redmond, D. E., Sondhi, D., Giannaris, E. L., Vassallo, E., Stratton, J., Qiu, J., Kaminsky, S. M., Lesser, M. L., Fisch, G. S., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1484 · Cited by 57
Self-citation
Cited by
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency
Mueller, C., Gernoux, G., Gruntman, A. M., Borel, F., Reeves, E. P., Calcedo, R., Rouhani, F. N., Yachnis, A., Humphries, M., Campbell-Thompson, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.029 · Cited by 112
“Other routes of delivery, such as intravenous or intrapleural, are also being investigated.(12) Intravenous delivery, similar to that used in the hemophilia B and hemophilia A trials, would almost certainly require the use of corticosteroids or other immune suppressive drugs.”
BackgroundThwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76
Rosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41
Self-citationGenetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Self-citation
Metadata
- Authors
- Chiuchiolo, M. J., Kaminsky, S. M., Sondhi, D., Hackett, N. R., Rosenberg, J. B., Frenk, E. Z., Hwang, Y., Van de Graaf, B. G., Hutt, J. A., Wang, G., Benson, J., & Crystal, R. G.
- Venue
- Human Gene Therapy Clinical Development
- Publisher
- SAGE Publications
- Published
- 2013-12
- Volume
- 24
- Issue
- 4
- Pages
- 161-173
- ISSN
- 2324-8637 (ISSN-L)
- 2324-8645
- OpenAlex
- W188582573
- Cited by
- 53
- References
- 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intrapleural Administration of an AAVrh.10 Vector Coding for Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency. https://app.cochat.ai/papers/10.1089/humc.2013.168
- The paper
- Chiuchiolo, M. J., Kaminsky, S. M., Sondhi, D., Hackett, N. R., Rosenberg, J. B., Frenk, E. Z., Hwang, Y., Van de Graaf, B. G., Hutt, J. A., Wang, G., Benson, J., & Crystal, R. G. (2013). Intrapleural Administration of an AAVrh.10 Vector Coding for Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development. https://doi.org/10.1089/humc.2013.168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.